What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Teclistamab has shown comparable efficacy to existing treatments, with an indirect comparison suggesting it increases overall survival and time to next treatment compared to pomalidomide plus dexamethasone. However, the lack of direct head-to-head trials and the high uncertainty surrounding the indirect treatment comparisons limit the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for teclistamab are within the acceptable range for Healthcare resources, particularly when considering the severity of the condition and the potential benefits of the treatment. The committee concluded that teclistamab could be recommended for routine commissioning based on its cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that teclistamab may improve quality of life for patients, particularly due to its corticosteroid-free regimen, which is noted to have a significant impact on patient well-being. However, the data is primarily anecdotal and lacks robust quantitative measures.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Teclistamab has a favorable safety profile, with manageable adverse effects reported. The absence of corticosteroids in its regimen is highlighted as a significant advantage, reducing the burden of side effects commonly associated with other treatments.
Was the drug compared against what payers expect? — Comparator Selection
The main comparator, pomalidomide plus dexamethasone, is appropriate; however, teclistamab has not been directly compared in trials with this treatment. The reliance on indirect comparisons introduces uncertainty regarding the validity of the results.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population for teclistamab is representative of the intended patient population, with a focus on those who have undergone multiple lines of treatment. However, there are some concerns regarding the generalizability of results from the real-world studies.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Teclistamab can be integrated into existing treatment pathways with minor adjustments, as it does not require new infrastructure or extensive training for healthcare professionals.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of teclistamab are manageable, with the potential for cost savings due to its efficacy and the absence of corticosteroids. The economic model supports its use within the Healthcare budget.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the evidence from the MajesTEC-1 trial is robust, the reliance on indirect comparisons and the limitations of the real-world studies introduce some uncertainty regarding the overall evidence quality.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty surrounding the indirect treatment comparisons and long-term outcomes. The committee noted that while teclistamab shows promise, the high level of uncertainty may restrict its use in practice.
